Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Alternative Evolutionary Paths to Bacterial Antibiotic Resistance Cause Distinct Collateral Effects.

Barbosa C, Trebosc V, Kemmer C, Rosenstiel P, Beardmore R, Schulenburg H, Jansen G.

Mol Biol Evol. 2017 Sep 1;34(9):2229-2244. doi: 10.1093/molbev/msx158.

2.

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.

Blondiaux N, Moune M, Desroses M, Frita R, Flipo M, Mathys V, Soetaert K, Kiass M, Delorme V, Djaout K, Trebosc V, Kemmer C, Wintjens R, Wohlkönig A, Antoine R, Huot L, Hot D, Coscolla M, Feldmann J, Gagneux S, Locht C, Brodin P, Gitzinger M, Déprez B, Willand N, Baulard AR.

Science. 2017 Mar 17;355(6330):1206-1211. doi: 10.1126/science.aag1006. Epub 2017 Mar 16.

PMID:
28302858
3.

A Novel Genome-Editing Platform for Drug-Resistant Acinetobacter baumannii Reveals an AdeR-Unrelated Tigecycline Resistance Mechanism.

Trebosc V, Gartenmann S, Royet K, Manfredi P, Tötzl M, Schellhorn B, Pieren M, Tigges M, Lociuro S, Sennhenn PC, Gitzinger M, Bumann D, Kemmer C.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7263-7271. Print 2016 Dec.

4.

Engineering of a Synthetic Metabolic Pathway for the Assimilation of (d)-Xylose into Value-Added Chemicals.

Cam Y, Alkim C, Trichez D, Trebosc V, Vax A, Bartolo F, Besse P, François JM, Walther T.

ACS Synth Biol. 2016 Jul 15;5(7):607-18. doi: 10.1021/acssynbio.5b00103. Epub 2015 Jul 24.

PMID:
26186096

Supplemental Content

Loading ...
Support Center